Initial combination therapy for early rheumatoid arthritis (RA) provides earlier clinical improvement and less progression of joint damage at 2 years compared with initial monotherapy, according to a randomized, controlled trial.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Research demonstrates better first-year results with combination therapy than with monotherapy in patients with early RA

Newsletter